Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Viruses ; 15(2)2023 02 08.
Article in English | MEDLINE | ID: mdl-36851682

ABSTRACT

The study aims to assess the usefulness of human T-cell leukemia virus type 1 (HTLV-1)-infected cell analysis using flow cytometry (HAS-Flow) as a monitoring method for adult T-cell leukemia (ATL) development in HTLV-1-positive patients with rheumatoid arthritis (RA) under treatment with antirheumatic therapies. A total of 13 HTLV-1-negative and 57 HTLV-1-positive RA patients participated in this study, which was used to collect clinical and laboratory data, including HAS-Flow and HTLV-1 proviral load (PVL), which were then compared between the two groups. CADM1 expression on CD4+ cells in peripheral blood (PB) was used to identify HTLV-1-infected cells. The population of CADM1+ CD4+ cells was significantly higher in HTLV-1-positive RA patients compared to HTLV-1-negative RA patients. The population of CADM1+ CD4+ cells was correlated with HTLV-1 PVL values. There were no antirheumatic therapies affecting both the expression of CADM1 on CD4+ cells and PVLs. Six HTLV-1-positive RA patients who indicated both high HTLV-1 PVL and a predominant pattern of CADM1+ CD7neg CD4+ cells in HAS-Flow can be classified as high-risk for ATL progression. HAS-Flow could be a useful method for monitoring high-risk HTLV-1-positive RA patients who are at risk of developing ATL during antirheumatic therapies.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Human T-lymphotropic virus 1 , Leukemia, T-Cell , Adult , Humans , Cross-Sectional Studies , Retrospective Studies , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Proviruses , Cell Adhesion Molecule-1
2.
Mod Rheumatol ; 32(5): 866-874, 2022 Aug 20.
Article in English | MEDLINE | ID: mdl-34897491

ABSTRACT

OBJECTIVES: We aimed to assess the clinical features of human T-cell leukaemia virus type 1 (HTLV-1)-positive rheumatoid arthritis (RA) patients. Furthermore, we investigated the impact of HTLV-1 infection on incidences of serious infections requiring hospitalisation (SIH) and malignancies. METHODS: A total of 150 sex- and age-matched HTLV-1-negative and 50 HTLV-1-positive RA patients were enrolled from the HTLV-1 RA Miyazaki Cohort Study. Clinical and laboratory data were collected from this cohort database. The incidence rate (IR) for SIH and malignancies from 2015 to 2020 was analysed. RESULTS: The median age and female ratio in the study population were 70 years old and 80%, respectively. Although no differences were found in inflammatory marker values between the two groups, the patient global assessment and Health Assessment Questionnaire scores were higher in HTLV-1-positive RA patients. In HTLV-1-negative RA patients, the IR for SIH was 6.37/100 person-years (PY) and 1.32/100 PY for malignancies. In HTLV-1-positive RA patients, SIH occurred in 11.1/100 PY and malignancies in 2.46/100 PY. The crude IR ratio comparing SIH between two groups was 1.74 (95% confidence interval, 1.04-2.84), which was a significant increase. CONCLUSIONS: HTLV-1-positive RA patients may worsen RA symptoms. HTLV-1 may be a risk factor for SIH.


Subject(s)
Arthritis, Rheumatoid , Human T-lymphotropic virus 1 , Leukemia, T-Cell , Aged , Arthritis, Rheumatoid/epidemiology , Cohort Studies , Female , Hospitalization , Humans , Incidence
3.
Mod Rheumatol ; 31(5): 972-978, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33161771

ABSTRACT

OBJECTIVES: Our previous study showed that the effectiveness of tumor necrosis factor (TNF) inhibitors was attenuated in anti-human T-cell leukemia virus type 1 (HTLV-1) antibody-positive patients with rheumatoid arthritis (RA). We aimed to evaluate the effectiveness and safety of non-TNF inhibitors in anti-HTLV-1 antibody-positive patients with RA. METHODS: We reviewed patients with RA who received abatacept or tocilizumab as the first biologic agent. We used the data of patients treated with TNF inhibitors from our previous study to compare the effectiveness between the anti-HTLV-1 antibody-positive patients treated with TNF inhibitors and non-TNF inhibitors using the inverse probability of treatment weights (IPTW) method. RESULTS: A total of 359 patients were divided into anti-HTLV-1 antibody-negative and -positive patients of 332 and 27, respectively. No statistically significant difference was observed in the change in the clinical disease activity index between the anti-HTLV-1 antibody-positive and -negative patients. The results using the IPTW method showed a significant association between the non-TNF inhibitors treatment and a better response. None of the patients developed adult T-cell leukemia/lymphoma or HTLV-1-associated myelopathy/tropical spastic paraparesis during the 24 weeks. CONCLUSION: Our results indicate that non-TNF inhibitors treatment is safety, and the effectiveness is not attenuated also in anti-HTLV-1 antibody-positive patients.


Subject(s)
Arthritis, Rheumatoid , Human T-lymphotropic virus 1 , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Humans , Leukemia-Lymphoma, Adult T-Cell , Paraparesis, Tropical Spastic/drug therapy , Tumor Necrosis Factor Inhibitors
4.
Mod Rheumatol Case Rep ; 5(1): 16-21, 2021 01.
Article in English | MEDLINE | ID: mdl-32772699

ABSTRACT

An elderly woman with rheumatoid arthritis (RA) presented with a chief complaint of abdominal pain and diarrhoea while undergoing treatment with low-dose corticosteroids and abatacept. Endoscopic and histopathological findings revealed manifestations of ulcerative colitis (UC). An intermediate dose of corticosteroids and 5-aminosalicylic acid were administered. Abatacept was discontinued; the anti-TNF biologic, golimumab, was administered for treatment of both RA and UC. However, colitis worsened in response to this therapeutic regimen. Colonoscopy revealed severe mucosal lesions; larvae were detected in samples taken from multiple shallow mucosal ulcers. The patient was diagnosed with Strongyloides stercoralis colitis based on the results of an anti-parasite antibody test and examination of the larval DNA. Furthermore, serology revealed a positive test for antibodies against human T-cell leukaemia virus type 1 (HTLV-1). Immunosuppressive treatment was terminated; ivermectin was administered, which resulted in improvements in colitis symptoms within a few weeks. There are several published reports describing S. stercoralis colitis as a lethal mimic of UC. Corticosteroid and anti-TNF therapies have been reported as among the major risk factors associated with strongyloidiasis in patients with HTLV-1 infection. Therefore, HTLV-1 and Strongyloides infections may be considered in cases of new-onset gastrointestinal symptoms during immunosuppressive therapy, particularly in HTLV-1-endemic regions.


Subject(s)
Arthritis, Rheumatoid/complications , Colitis, Ulcerative/chemically induced , HTLV-I Infections/complications , Immunosuppressive Agents/adverse effects , Strongyloides stercoralis/isolation & purification , Strongyloidiasis/complications , Aged , Animals , Antiparasitic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Colitis, Ulcerative/pathology , Female , HTLV-I Infections/diagnosis , HTLV-I Infections/drug therapy , Human T-lymphotropic virus 1/isolation & purification , Humans , Ivermectin/therapeutic use , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Tumor Necrosis Factor Inhibitors/therapeutic use
5.
PLoS One ; 15(5): e0233159, 2020.
Article in English | MEDLINE | ID: mdl-32459801

ABSTRACT

BACKGROUND: CD4-positive T cells are the main target of human T-cell leukemia virus type 1 (HTLV-1). Interferon-γ release assays rely on the fact that T-lymphocytes release this cytokine when exposed to tuberculosis-specific antigens and are useful in testing for latent tuberculosis infection before initiating biologic therapy, such as anti-tumor necrosis factor agents. However, the reliability of interferon-γ release assays in detecting tuberculosis infection among HTLV-1-positive patients with rheumatoid arthritis (RA) remains unclear. The present study aimed to evaluate the use of the T-SPOT.TB assay in HTLV-1-positive RA patients. METHODS: Overall, 29 HTLV-1-positive RA patients and 87 age- and sex-matched HTLV-1-negative RA patients (controls) were included from the HTLV-1 RA Miyazaki Cohort Study. Results of the T-SPOT.TB assay for latent tuberculosis infection screening were collected from medical records of patients. RESULTS: Approximately 55% of the HTLV-1-positive RA patients showed invalid T-SPOT.TB assay results (odds ratio: 108, 95% confidence interval: 13.1-890, p < 0.0001) owing to a spot count of >10 in the negative controls. HTLV-1 proviral load values were significantly higher in patients with invalid results compared with those without invalid results (p = 0.003). CONCLUSION: HTLV-1 infection affects T-SPOT.TB assay results in RA patients. Assay results in HTLV-1 endemic regions should be interpreted with caution when screening for latent tuberculosis infection before initiation of biologic therapy.


Subject(s)
Arthritis, Rheumatoid/immunology , CD4-Positive T-Lymphocytes/immunology , HTLV-I Infections/immunology , Human T-lymphotropic virus 1/immunology , Interferon-gamma Release Tests , Tuberculosis/immunology , Aged , Aged, 80 and over , Arthritis, Rheumatoid/microbiology , Arthritis, Rheumatoid/pathology , Arthritis, Rheumatoid/virology , CD4-Positive T-Lymphocytes/pathology , Female , HTLV-I Infections/microbiology , HTLV-I Infections/pathology , Humans , Male , Middle Aged , Tuberculosis/microbiology , Tuberculosis/pathology , Tuberculosis/virology
6.
Mod Rheumatol ; 29(5): 795-801, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30246572

ABSTRACT

Objective: This study aimed to investigate the time-sequential changes of risk factors for adult T-cell leukemia (ATL) development in human T-cell leukemia virus type 1 (HTLV-1)-positive rheumatoid arthritis (RA) patients. Methods: HTLV-1 infection was screened using particle agglutination assay and confirmed via western blotting in 365 RA patients. Twenty-three HTLV-1-positive RA patients were included in the study cohort. Blood samples were obtained from these patients at each observation time point. The values of HTLV-1 proviral load (PVL) and serum soluble IL-2 receptor (sIL2-R), which are risk factors for ATL development, were measured using real-time PCR and enzyme immunoassay, respectively. Results: The study cohort comprised 79 person-years. The median HTLV-1 PVL and sIL2-R values of the HTLV-1-positive RA patients were 0.44 copies per 100 white blood cells (WBCs) and 406 U/mL, respectively. Three HTLV-1-positive RA patients showed a high PVL value. No remarkable changes were observed in the PVL and sIL2-R values during the observation period. However, one elderly HTLV-1-positive RA patient who had a high PVL value developed ATL during treatment with methotrexate and infliximab. Conclusion: A thorough clinical assessment of the risk factors for ATL development may be necessary in daily clinical practice for RA patients in HTLV-1-endemic areas in Japan.


Subject(s)
Arthritis, Rheumatoid/epidemiology , HTLV-I Infections/epidemiology , Leukemia-Lymphoma, Adult T-Cell/epidemiology , Adult , Aged , Arthritis, Rheumatoid/complications , Female , HTLV-I Infections/complications , Humans , Japan , Male , Middle Aged
7.
Transfus Apher Sci ; 56(5): 698-702, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28918917

ABSTRACT

In this article, we discussed leukocytapheresis (LCAP) for rheumatoid arthritis (RA). Recently, a simple and practical on-line continuous LACP system has been developed. It is equipped with a direct hemoperfusion column (Cellsorba®, Asahikasei Medical Co., Ltd.) packed with fine-diameter polyester fibers, which are commonly used to adsorb white blood cells to prevent a graft-versus-host reaction during blood transfusion. Clinical trials revealed that LCAP is a effective and safe therapy for patients with drug-resistant RA or RA complicated with vasculitis. Because the procedure is simple and requires no plasma substitutes and the volume needed for extracorporeal circulation is less than that for other plasmapheresis, LCAP might be accepted as an optional therapeutic modality for active RA that was refractory to conventional drug therapy including biological agents. The mechanism of the efficiency of LCAP on RA is unclear. LCAP may cause a reduction of activated T cells from affected joints, down-regulation of Pgp on helper T cells and restoration of Treg function, and that may modify the abnormal cytokine balance. These findings may explain some of the mechanisms by which the articular symptoms are improved by LCAP.


Subject(s)
Arthritis, Rheumatoid/therapy , Leukapheresis/methods , Arthritis, Rheumatoid/blood , Humans
8.
PLoS One ; 12(6): e0179179, 2017.
Article in English | MEDLINE | ID: mdl-28594905

ABSTRACT

OBJECTIVE: Knowing the risk of hospitalized infection associated with individual biological agents is an important factor in selecting the best treatment option for patients with rheumatoid arthritis (RA). This study examined the comparative risk of hospitalized infection between biological agents in a routine care setting. METHODS: We used data for all RA patients who had first begun biological therapy at rheumatology divisions of participating community hospitals in Japan between January 2009 and December 2014. New treatment episodes with etanercept, infliximab, adalimumab, abatacept, or tocilizumab were included. Patients were allowed to contribute multiple treatment episodes with different biological agents. Incidence rates (IRs) of hospitalized infection during the first year of follow-up were examined. Cox regression analysis was used to calculate hazard ratios (HRs) for overall hospitalized infection and for pulmonary hospitalized infection, adjusting for possible confounders. RESULTS: A total of 1596 new treatment episodes were identified. The incidence of overall hospitalized infection during the first year was 86 with 1239 person-years (PYs), yielding a crude IR of 6.9 per 100 PYs (95% confidence interval [CI], 5.6-8.6). After correction for confounders, no significant difference in risk of hospitalized infection was observed between treatment groups: adjusted HRs (95% CI) were 1.54 (0.78-3.04) for infliximab, 1.72 (0.88-3.34) for adalimumab, 1.11 (0.55-2.21) for abatacept, and 1.02 (0.55-1.87) for tocilizumab compared with etanercept. Patient-specific factors such as age, RA functional class, body mass index (BMI), prednisolone use, and chronic lung disease contributed more to the risk of hospitalized infection than specific biological agents. The incidence of pulmonary hospitalized infection was 50 and a crude IR of 4.0 per 100 PYs (95% CI, 3.1-5.3). After adjustment for confounders, adalimumab had a significantly higher HR for pulmonary hospitalized infection compared with tocilizumab: an adjusted HR (95% CI) was 4.43 (1.72-11.37) for adalimumab. BMI, prednisolone use, diabetes mellitus, and chronic lung disease were also significant factors associated with the risk of pulmonary hospitalized infection. CONCLUSIONS: The magnitude of the risk of overall hospitalized infection was not determined by the type of biological agents, and patient-specific risk factors had more impact on the risk of hospitalized infection. For pulmonary hospitalized infections, the use of adalimumab was significantly associated with a greater risk of this complication than tocilizumab use.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Biological Factors/therapeutic use , Cross Infection/epidemiology , Arthritis, Rheumatoid/mortality , Demography , Female , Follow-Up Studies , Humans , Incidence , Japan/epidemiology , Male , Middle Aged , Respiratory Tract Infections/epidemiology , Retrospective Studies , Risk Factors
9.
Arthritis Care Res (Hoboken) ; 66(5): 788-92, 2014 May.
Article in English | MEDLINE | ID: mdl-24127184

ABSTRACT

OBJECTIVE: To investigate the response to and safety of anti­tumor necrosis factor (anti-TNF) therapy in human T lymphotropic virus type I (HTLV-I)­positive patients with rheumatoid arthritis (RA). METHODS: Therapeutic response was evaluated in 10 HTLV-I­positive and 20 HTLV-I­negative patients with RA (sex and age matched) at 3 months after the beginning of anti-TNF therapy using the European League Against Rheumatism improvement criteria. As secondary end points, the discontinuation rate of anti-TNF therapy and its safety, especially the development of adult T cell leukemia (ATL), were evaluated over a 2-year period. RESULTS: Significantly higher baseline levels of C-reactive protein (CRP) were observed in HTLV-I­positive patients than in HTLV-I­negative patients (P = 0.0003). The response rate to anti-TNF therapy was lower in HTLV-I­positive patients than in HTLV-I­negative patients. The median CRP level, erythrocyte sedimentation rate, and Disease Activity Score in 28 joints at 3 months after anti-TNF treatment in HTLV-I­positive patients were significantly higher than in HTLV-I­ negative patients (P = 0.003, P = 0.03, and P = 0.003, respectively). The discontinuation rate due to insufficient response was significantly higher in HTLV-I­positive patients than in HTLV-I­negative patients (P = 0.013). During the 2-year observation period, no patients developed ATL. CONCLUSION: These data suggest that HTLV-I­positive patients with RA had higher inflammation and greater resistance to anti-TNF treatment than HTLV-I­negative patients. Further study is necessary to determine whether HTLV-I infection should be measured when anti-TNF agents are administered to patients with RA, especially in areas were HTLV-I is endemic.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Factors/therapeutic use , HTLV-I Infections/drug therapy , Human T-lymphotropic virus 1 , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Aged , Aged, 80 and over , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/immunology , Biological Factors/pharmacology , Female , HTLV-I Infections/blood , HTLV-I Infections/immunology , Human T-lymphotropic virus 1/metabolism , Humans , Infliximab , Male , Middle Aged , Retrospective Studies , Treatment Outcome
12.
J Vet Med Sci ; 73(11): 1477-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21705847

ABSTRACT

Neonatal Japanese Black (JB) calves show a high incidence of diarrhea. The objective of this study was to analyze the immune cell populations of neonatal JB calves in detail and examine its correlation with the incidence of diarrhea immediately after birth. Understanding the immune cell populations is helpful in clinics in order to determine the condition of the immune system for prevention of diseases. Blood samples were obtained from JB calves on the day of birth. The peripheral leukocyte populations were analyzed separately for calves that had diarrhea within 2 weeks after birth (diarrhea group; n = 26) and for calves without diarrhea (control group; n = 74). The numbers of the peripheral blood CD3(+)TcR1-N12(+) and CD8(+) T cells were significantly lower in the diarrhea group compared with the control group. These findings suggest that the congenital lower peripheral γδ and CD8(+) T cells results in a high risk of diarrhea in neonatal JB calves.


Subject(s)
Cattle Diseases/immunology , Diarrhea/veterinary , T-Lymphocytes/metabolism , Animals , Case-Control Studies , Cattle , Cattle Diseases/blood , Diarrhea/blood , Diarrhea/immunology , Female , Leukocyte Count/veterinary , Lymphocyte Count/veterinary , Male
13.
J Vet Med Sci ; 70(2): 193-6, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18319582

ABSTRACT

The effects of mycotoxins on mitogen-stimulated proliferation of bovine peripheral blood mononuclear cells (PBMCs) were investigated. Aflatoxin B(1) (AFB(1)), deoxynivalenol (DON) and zearalenone (ZEN) were added to cultures of PBMCs, and the proliferation responses were measured using MTT bioassays. Suppression of the proliferation of calf PBMCs by AFB(1) and DON was significantly stronger than that of cow PBMCs, whereas there were no differences in suppressive effects on PBMCs from Holstein and Japanese Black calves and cows. The suppressive effect was greatest in the order of DON, AFB(1) and ZEN, and the effects of DON and AFB(1) seemed to be dose-dependent. The results suggest that some mycotoxins directly suppress proliferation of bovine PBMCs.


Subject(s)
Cattle , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Mitogens/pharmacology , Mycotoxins/pharmacology , Animals , Cell Proliferation/drug effects , Cells, Cultured , Dose-Response Relationship, Drug
SELECTION OF CITATIONS
SEARCH DETAIL
...